What is Argireline?
Argireline is an acetylated hexapeptide used in cosmetics. A short placebo-controlled trial studied a topical formulation for wrinkles around the eyes.
Biological role or research focus
Topical wrinkle-formulation research.
Short cosmetic follow-up cannot establish durable effects, all-serum equivalence, or equivalence to botulinum toxin injection.
Role reference: The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. · 2013 ↗
Names you may encounter
Acetyl hexapeptide-8 · Acetyl hexapeptide-3
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Acetylated hexapeptide cosmetic ingredient
- Research focus
- Topical wrinkle-formulation research
- Featured evidence
- Human randomized cosmetic trial
- Source check
- October 4, 2026
Quick answers
- Is Argireline FDA approved?
- No. No FDA-approved drug contains Argireline. Source ↗
- Is Argireline safe?
- Argireline (acetyl hexapeptide-8) is a cosmetic ingredient tested in short skin-applied wrinkle trials. Published safety detail is thin, and long-term use, irritation and allergy are not well studied. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Argireline banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Argireline for peri-orbital wrinkles (2013) | Human randomized cosmetic trial | 60 Chinese participants with peri-orbital wrinkles. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized cosmetic trial · 2013
Argireline for peri-orbital wrinkles
What did this publication test, and what did it find?
- Population / model
- 60 Chinese participants with peri-orbital wrinkles.
- Study design
- Four-week randomized placebo-controlled study with a 3:1 active-to-placebo allocation.
- Main finding
- The publication reported improved wrinkle grading and skin-roughness measurements with the Argireline formulation.
- Limits & context
- Short cosmetic follow-up cannot establish durable effects, all-serum equivalence, or equivalence to botulinum toxin injection.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
4 registered studies name Argireline as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 3 completed and 1 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin NCT02597777 · University of California, Davis | Completed | Not applicable | 2016-01 | 14 |
| Acetyl Hexapeptide-8 for Blepharospasm NCT01750346 · National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | Phase 2 | 2012-11 | 8 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm NCT00942851 · National Institute of Neurological Disorders and Stroke (NINDS) | Completed | Phase 1 / Phase 2 | 2009-07 | 24 |
| Argireline in Treatment of Periorbital Wrinkles NCT01381484 · Mahidol University | Completed | Phase 3 | 2009-03 | 70 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Cosmeceuticals in photoaging: A review. ↗
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024 Sep · Journal Article, Systematic Review
Read available full text ↗
A synthetic hexapeptide (Argireline) with antiwrinkle activity. ↗
International journal of cosmetic science · 2002 Oct · Journal Article
The anti-wrinkle efficacy of Argireline. ↗
Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2013 Aug · Journal Article
Argireline: Needle-Free Botox as Analytical Challenge. ↗
Chemistry & biodiversity · 2021 Mar · Journal Article
Risks & interactions
Argireline (acetyl hexapeptide-8) is a cosmetic ingredient tested in short skin-applied wrinkle trials. Published safety detail is thin, and long-term use, irritation and allergy are not well studied.
Human evidence is limited to small, short cosmetic trials of skin-applied formulas, such as a four-week placebo-controlled study in 60 people. These do not establish the tolerability of every finished product, long-term use, or any use other than on the skin.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Argireline anti-wrinkle randomized placebo-controlled study (2013) ↗ · A synthetic hexapeptide (Argireline) with antiwrinkle activity (2002) ↗
Safety & what remains unknown
Topical-formulation observations do not establish injection safety or tolerability of every finished cosmetic product.
Evidence boundaries
Short cosmetic follow-up cannot establish durable effects, all-serum equivalence, or equivalence to botulinum toxin injection.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. It is a cosmetic ingredient; WADA's S0 catch-all addresses pharmacological substances, and its application to topical cosmetic ingredients was not determined. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The selected evidence is specific to topical application and a tested formulation. Older publications may use the acetyl hexapeptide-3 name; current ingredient labels may use acetyl hexapeptide-8.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
The ingredient is discussed in relation to SNARE-associated signaling. A proposed mechanism does not establish the clinical action of an injectable neuromodulator.
Questions worth asking
- Is topical Argireline equivalent to injected botulinum toxin?
- What material, population, and route were actually studied?
- Short cosmetic follow-up cannot establish durable effects, all-serum equivalence, or equivalence to botulinum toxin injection.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is topical Argireline equivalent to injected botulinum toxin?
No. The formulation, route, mechanism, and supporting clinical evidence differ.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
